Thermo Fisher Scientific Gets FDA Clearance for Preeclampsia Risk Assessment Assays
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of developing a severe pregnancy complication known as preeclampsia.
The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) assays run in 30 minutes on the BRAHMS KRYPTOR chemistry analyzer and are the first and only immunoassays to date to receive breakthrough designation and clearance from the FDA to assess risk and aid in clinical management of preeclampsia, the firm said in a statement.
Preeclampsia, a life-threatening blood pressure disorder, is the leading cause of maternal and fetal mortality and morbidity worldwide. Incidence rates for the condition have increased rapidly in the US. (For more on understanding the placental origins of preeclampsia, see our Causes of Preeclampsia article.)
These new assays can be used along with other lab tests and clinical assessments to assess whether pregnant people who have been hospitalized for hypertensive disorders of pregnancy are at risk of progressing to preeclampsia with severe features within the subsequent two weeks.
"Today's clearance of these breakthrough biomarkers will have a significant impact on prognosis and treatment for thousands of women at risk for preeclampsia every year in the US," said Alan Sachs, chief medical officer at Thermo Fisher Scientific.
The assays have been validated by a research study, which examined more than 700 pregnant people in 18 hospitals. Patients who test positive based on a risk stratification ratio of the two assays within a hospital setting could receive enhanced surveillance and accelerated care before severe features develop.
"Patients and providers will benefit from having better tests to predict progression to preeclampsia with severe features, especially for those patients at risk of severe, early-onset disease or for whom there is some diagnostic uncertainty," said Eleni Tsigas, CEO at the Preeclampsia Foundation. "Our organization celebrates this result after many years of advocacy with leaders in research and regulatory bodies, such as the FDA, to accelerate the development and adoption of better clinical tools."
For more on the Preeclampsia Foundation's work to amplify all research related to biomarkers for improved prediction and diagnostic tools, please visit https://preeclampsia.org/biomarkers.
Related Articles
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Development and validation of a new algorithm for improved cardiovascular risk prediction Heart disease or cardiovascular disease (CVD) is a leading cause of death worldwide. An individual&r...
Women With a History of Preeclampsia Exhibit Accelerated Aging and Unfavorable Profiles of Senescence Markers Scientists conducted a study to see if women with preeclampsia were more likely...
Feasibility of home-based treatment among participants in a remote postpartum hypertension program Postpartum hypertension (high blood pressure after pregnancy) is the most common reason for...
Postpartum Ambulatory Blood Pressure Patterns Following New-Onset Hypertensive Disorders of Pregnancy After experiencing gestational hypertension or preeclampsia, high blood pressure can wors...
Patterns of Gestational Hypertension or Preeclampsia Across 2 Pregnancies in Relationship to Chronic Hypertension Development: A Retrospective Cohort Study Experiencing preeclampsia or gestat...